148 related articles for article (PubMed ID: 27440728)
1. Epigenetic activation of the drug transporter OCT2 sensitizes renal cell carcinoma to oxaliplatin.
Liu Y; Zheng X; Yu Q; Wang H; Tan F; Zhu Q; Yuan L; Jiang H; Yu L; Zeng S
Sci Transl Med; 2016 Jul; 8(348):348ra97. PubMed ID: 27440728
[TBL] [Abstract][Full Text] [Related]
2. Regulation of
Zhu Q; Yu L; Qin Z; Chen L; Hu H; Zheng X; Zeng S
Epigenetics; 2019 Aug; 14(8):791-803. PubMed ID: 31088315
[TBL] [Abstract][Full Text] [Related]
3. The failure of DAC to induce OCT2 expression and its remission by hemoglobin-based nanocarriers under hypoxia in renal cell carcinoma.
Chen L; Wang Z; Xu Q; Liu Y; Chen L; Guo S; Wang H; Zeng K; Liu J; Zeng S; Yu L
Theranostics; 2020; 10(8):3562-3578. PubMed ID: 32206108
[No Abstract] [Full Text] [Related]
4. Upregulation of miR-489-3p and miR-630 inhibits oxaliplatin uptake in renal cell carcinoma by targeting OCT2.
Chen L; Chen L; Qin Z; Lei J; Ye S; Zeng K; Wang H; Ying M; Gao J; Zeng S; Yu L
Acta Pharm Sin B; 2019 Sep; 9(5):1008-1020. PubMed ID: 31649850
[TBL] [Abstract][Full Text] [Related]
5. Kidney-specific expression of human organic cation transporter 2 (OCT2/SLC22A2) is regulated by DNA methylation.
Aoki M; Terada T; Kajiwara M; Ogasawara K; Ikai I; Ogawa O; Katsura T; Inui K
Am J Physiol Renal Physiol; 2008 Jul; 295(1):F165-70. PubMed ID: 18508876
[TBL] [Abstract][Full Text] [Related]
6. Response to Comment on "Epigenetic activation of the drug transporter OCT2 sensitizes renal cell carcinoma to oxaliplatin".
Zheng X; Liu Y; Yu Q; Wang H; Tan F; Zhu Q; Yuan L; Jiang H; Zeng S; Yu L
Sci Transl Med; 2017 May; 9(391):. PubMed ID: 28539476
[No Abstract] [Full Text] [Related]
7. Fluorocholine Transport Mediated by the Organic Cation Transporter 2 (OCT2, SLC22A2): Implication for Imaging of Kidney Tumors.
Visentin M; Torozi A; Gai Z; Häusler S; Li C; Hiller C; Schraml PH; Moch H; Kullak-Ublick GA
Drug Metab Dispos; 2018 Aug; 46(8):1129-1136. PubMed ID: 29794161
[TBL] [Abstract][Full Text] [Related]
8. Comment on "Epigenetic activation of the drug transporter OCT2 sensitizes renal cell carcinoma to oxaliplatin".
Winter S; Fisel P; Büttner F; Nies AT; Stenzl A; Bedke J; Schwab M; Schaeffeler E
Sci Transl Med; 2017 May; 9(391):. PubMed ID: 28539468
[No Abstract] [Full Text] [Related]
9. Organic cation transporter 2 activation enhances sensitivity to oxaliplatin in human pancreatic ductal adenocarcinoma.
Chiu CF; Park JM; Chen HH; Mau CZ; Chen PS; Su YH; Chen HA; Liu YR; Hsieh TH; Chiu CC; Hung SW; Kuo CY; Chen YM; Chang CF
Biomed Pharmacother; 2022 Sep; 153():113520. PubMed ID: 36076515
[TBL] [Abstract][Full Text] [Related]
10. Methylation of the gamma-catenin gene is associated with poor prognosis of renal cell carcinoma.
Breault JE; Shiina H; Igawa M; Ribeiro-Filho LA; Deguchi M; Enokida H; Urakami S; Terashima M; Nakagawa M; Kane CJ; Carroll PR; Dahiya R
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):557-64. PubMed ID: 15701841
[TBL] [Abstract][Full Text] [Related]
11. Oxaliplatin-induced neurotoxicity is dependent on the organic cation transporter OCT2.
Sprowl JA; Ciarimboli G; Lancaster CS; Giovinazzo H; Gibson AA; Du G; Janke LJ; Cavaletti G; Shields AF; Sparreboom A
Proc Natl Acad Sci U S A; 2013 Jul; 110(27):11199-204. PubMed ID: 23776246
[TBL] [Abstract][Full Text] [Related]
12. JBP485 attenuates vancomycin-induced nephrotoxicity by regulating the expressions of organic anion transporter (Oat) 1, Oat3, organic cation transporter 2 (Oct2), multidrug resistance-associated protein 2 (Mrp2) and P-glycoprotein (P-gp) in rats.
Wen S; Wang C; Huo X; Meng Q; Liu Z; Yang S; Zhu Y; Sun H; Ma X; Liu K
Toxicol Lett; 2018 Oct; 295():195-204. PubMed ID: 29964132
[TBL] [Abstract][Full Text] [Related]
13. DNA methylation of the SLC16A3 promoter regulates expression of the human lactate transporter MCT4 in renal cancer with consequences for clinical outcome.
Fisel P; Kruck S; Winter S; Bedke J; Hennenlotter J; Nies AT; Scharpf M; Fend F; Stenzl A; Schwab M; Schaeffeler E
Clin Cancer Res; 2013 Sep; 19(18):5170-81. PubMed ID: 23881922
[TBL] [Abstract][Full Text] [Related]
14. Remodeling epigenetic modifications at tumor suppressor gene promoters with bovine oocyte extract.
Wang Z; Yue Y; Han P; Sa R; Ren X; Wang J; Bai H; Yu H
Cytotherapy; 2013 Sep; 15(9):1164-73. PubMed ID: 23800731
[TBL] [Abstract][Full Text] [Related]
15. DNA Methylation Signature Reveals Cell Ontogeny of Renal Cell Carcinomas.
Malouf GG; Su X; Zhang J; Creighton CJ; Ho TH; Lu Y; Raynal NJ; Karam JA; Tamboli P; Allanick F; Mouawad R; Spano JP; Khayat D; Wood CG; Jelinek J; Tannir NM
Clin Cancer Res; 2016 Dec; 22(24):6236-6246. PubMed ID: 27256309
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic inactivation of HOXA11, a novel functional tumor suppressor for renal cell carcinoma, is associated with RCC TNM classification.
Wang L; Cui Y; Sheng J; Yang Y; Kuang G; Fan Y; Jin J; Zhang Q
Oncotarget; 2017 Mar; 8(13):21861-21870. PubMed ID: 28423531
[TBL] [Abstract][Full Text] [Related]
17. Effects of genetic polymorphisms on the OCT1 and OCT2-mediated uptake of ranitidine.
Meyer MJ; Seitz T; Brockmöller J; Tzvetkov MV
PLoS One; 2017; 12(12):e0189521. PubMed ID: 29236753
[TBL] [Abstract][Full Text] [Related]
18. Alterations of the spindle checkpoint pathway in clinicopathologically aggressive CpG island methylator phenotype clear cell renal cell carcinomas.
Arai E; Gotoh M; Tian Y; Sakamoto H; Ono M; Matsuda A; Takahashi Y; Miyata S; Totsuka H; Chiku S; Komiyama M; Fujimoto H; Matsumoto K; Yamada T; Yoshida T; Kanai Y
Int J Cancer; 2015 Dec; 137(11):2589-606. PubMed ID: 26061684
[TBL] [Abstract][Full Text] [Related]
19. Incorporating renal excretion via the OCT2 transporter in physiologically based kinetic modelling to predict in vivo kinetics of mepiquat in rat.
Noorlander A; Wesseling S; Rietjens IMCM; van Ravenzwaay B
Toxicol Lett; 2021 Jun; 343():34-43. PubMed ID: 33639197
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic inactivation of the candidate tumor suppressor gene HOXB13 in human renal cell carcinoma.
Okuda H; Toyota M; Ishida W; Furihata M; Tsuchiya M; Kamada M; Tokino T; Shuin T
Oncogene; 2006 Mar; 25(12):1733-42. PubMed ID: 16278676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
